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Preoperative endocrine therapy is effective in postmenopausal patients with breast cancers expressing oestrogen receptor. We
investigated the activity of primary therapy with letrozole in combination with GnRH analogue in premenopausal women with
T2–T4 N0–N2 breast cancer, whose tumours expressed oestrogen and progesterone receptors. We measured the expression of
molecular factors involved in responsiveness to endocrine agents including ERa, EGFR, HER2, MAP kinases (and phosphorylated
forms) ER-b1, both at initial biopsy and at the time of surgery. Thirty-five patients were included and 32 patients were evaluable for
response. Sixteen patients (50%, 95% CI 32–68%) obtained a partial response, 16 patients were stable. One patient showed
pathological complete response (3%, 95% CI 0–16%). Response was significantly associated with younger age (Po0.05) and a longer
duration of treatment (Po0.05). Treatment significantly decreased ERa-p-Ser
118 and upregulated ER-b1, independently of response.
No or negligible overexpression of EGFR was observed at baseline or after treatment in this population. Preoperative letrozole and
GnRH analogue are effective in premenopausal women. A biological response in terms of downregulation of phosphorylated ERa
was observed in all patients. Future investigations might focus on treatments of longer duration.
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Preoperative cytotoxic therapy has proved less effective in women
with breast cancers expressing oestrogen receptor (ER) (Colleoni
et al, 2004; Kaufmann et al, 2006). Endocrine therapy is a logical
alternative. In postmenopausal women, neoadjuvant treatment
with aromatase inhibitors showed promising results, better than
those observed with tamoxifen (Eiermann et al, 2001; Miller et al,
2001; Smith et al, 2005; Abrial et al, 2006).
In premenopausal women, the use of aromatase inhibitors leads
to an increase in gonadotropin secretion because of the reduced
feedback of oestrogens on hypothalamus and pituitary and a
subsequent stimulation of ovarian activity (Smith and Dowsett,
2003). The combination of aromatase inhibitors with GnRH
analogue can obtain a complete oestrogen blockade by suppression
of ovarian function and of peripheral oestrogen synthesis (Smith
and Dowsett, 2003). However, limited experience has been
described with aromatase inhibitors in combination with ovarian
function suppression in premenopausal women with advanced
breast cancer (Forward et al, 2004). Aromatase inhibitors in
combination with GnRH analogues have not been systematically
studied as preoperative therapy in premenopausal women with
locally advanced operable breast cancer.
Mechanisms underlying responsiveness and/or resistance to
aromatase inhibitors are poorly understood. It has been proposed
that tumour cells may escape the inhibitory effects of antioestrogens
by increasing ligand-independent phosphorylation of ER, possibly as
a result of an overexpression of growth factors, namely the EGFR,
Her-2/neu (HER2) and the IGF-IR pathways through increased levels
of mitogen-activated protein kinases (MAPKs) (Chen et al,2 0 0 2 ;
Lannigan, 2003). The low levels of the isoform b of ER have been
associated with resistance to tamoxifen (Esslimani-Sahla et al,2 0 0 4 ;
Hopp et al, 2004), but further data failed to show any association
with response to preoperative toremifene (Cappelletti et al, 2004).
In the present study, we investigated the antitumour activity and
expression of biological factors in a selected population of
premenopausal patients with locally advanced breast cancer whose
tumours expressed both ER and progesterone receptor (PgR) in at
least 10% of tumour cells. Given the limited knowledge on the
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sendocrine effects of aromatase inhibitors in premenopausal
women, we also measured sequential 17-b-oestradiol levels in a
subgroup of patients for whom repeated measurements were
available.
PATIENTS AND METHODS
Premenopausal patients with histologically proven T2–T4b breast
cancer whose tumours showed ER and PgR immunoreactivity in
X10% of cells, consecutively admitted at the Department of
Medicine of the European Institute of Oncology from January 2002
to April 2004 were enrolled in the study. All patients were
submitted to a core biopsy using an 18gauge needle of the primary
tumour for histological diagnosis and assessment of biological
characteristics (hormone receptor status, Ki-67 labelling index and
immunoreactivity for HER2).
All patients were premenopausal as assessed by measurement of
circulating oestradiol and gonadotrophins within the premeno-
pausal range according to the reference value for each laboratory,
and/or regular menses in the past 6 months. Investigations (chest
X-ray, abdomen ultrasound and bone scan) were performed to
exclude distant metastasis and blood tests were performed to
assess bone marrow, renal and hepatic function within 2 weeks of
inclusion in the study.
The primary tumour was measured clinically by calliper in two
principal diameters and by breast ultrasound and mammography.
Tumour response was assessed clinically every month and by
breast ultrasound and mammography after 2 and 4 months of
treatment. Clinical response was defined according to WHO
criteria, as X50% reduction of the product of two diameters of the
tumour measured by calliper by the same examiner and by at least
one medical imaging examination. Patients were submitted
routinely to surgery after the second evaluation. A pathological
complete remission (pCR) was defined as a total disappearance of
the invasive tumour in both breast and axillary lymph nodes
(Kuerer et al, 1999).
Endocrine therapy commenced with ovarian suppression
obtained by means of a GnRH analogue, which was administered
as intramuscular triptorelin 11.25mg every 3 months. The
aromatase inhibitor letrozole 2.5mg per day was added when
circulating oestradiol was in the postmenopausal range according
to each laboratory reference value and was administered for at
least 3 months. Oestradiol and gonadotrophin levels were repeated
monthly during treatment with letrozole in order to verify the
maintenance of ovarian function suppression.
Written informed consent was obtained from all patients. The
Protocol was notified to the Ethical Committee.
This is a single institution study. All included patients had
pathological evaluation performed at the EIO. Surgical specimens
were extensively sampled for the evaluation of residual tumour
as previously described (Colleoni et al, 2004). Immunostaining
experiments for the localisation of ER (clone ID5, DakoCytoma-
tion, Glostrup, Denmark, pretreatment with EDTA, at 1:100
dilution) and PgR (636, DakoCytomation, EDTA, 1:400), Her2/neu
protein (polyclonal antibody, DakoCytomation, EDTA, 1:800) and
Ki-67 antigen (MIB-1, DakoCytomation, EDTA, 1:200) were
performed on consecutive tissue sections of the diagnostic biopsies
and residual tumour after surgery, if any, as previously reported
(Colleoni et al, 2004).
Furthermore, we also investigated the prevalence and the
predictive role of the immunoreactivity for phospho-ERa (Ser
118)
(pERa, polyclonal antibody, Cell Signaling Technology Inc.
(Danvers, MA, USA) EDTA, 1:100), ER-b1 (PP-G5/10, DakoCyto-
mation, citrate, 1:20), epidermal growth factor receptor (EGFR,
31G7, Zymed Laboratories (San Francisco, CA, USA) pronase,
1:20), phospho-EGFR (p-EGFR, polyclonal antibody, Cell Signal-
ing, EDTA, 1:400), phospho-HER2 (p-HER2, polyclonal antibody,
DakoCytomation, EDTA, 1:200), phospho-p38 (p-p38MAPK,
12F8, Cell Signaling, citrate, 1:100) and phospho–p44/42 (p-p44/
42MAPK, 20G11, Cell Signaling, citrate, 1:100) MAP-kinases in a
subgroup of 27 patients for whom tumour tissue from both
diagnostic biopsies and post-treatment surgical specimens was
available.
In each case at least 200 neoplastic cells were evaluated at  400
magnification and the percentage of cells showing any definite
nuclear (for ER, PgR and Ki-67) and membranous (for EGFR, HER2
and their phosphorylated forms) immunoreactivity was recorded.
The immunostained slides were evaluated independently by two
of the authors. The thresholds for hormone receptors (ER and
PgR) and Ki-67 labelling index were 10 and 20%, respectively,
according to published studies and the routine practice. The value
of 20% for proliferative activity was selected based on previous
data from our group indicating that this threshold significantly
correlated with higher response rate to preoperative chemotherapy
(Colleoni et al, 2004). For HER2, we used the FDA approved score
system.
Finally, cutoffs for p-ERa-Ser
118, ER-b, EGFR, pEGFR, pHER2,
p-p-38 (MAPK) and p-p44/42 (MAPK) have not been defined yet,
since they have not been extensively investigated and are not used
in the routine clinical practice, therefore samples containing any
percentage of stained cells were considered positive.
The main end point of this study was clinical response.
According to literature (Eiermann et al, 2001; Gazet et al, 2001;
Smith et al, 2005), we expected to observe at least 45% of clinical
responses. We adopted an optimal two-stage design, with a target
rate of clinical responses of 45% deemed acceptable, and a
response rate of 22% considered unacceptable.
For a 0.1 type I error and a 0.1 type II error probabilities, 17
patients were needed in the first stage and if 4 or less achieved
an objective response the study had to be closed for insufficient
activity. If 5 or more objective responses were observed among
these initial patients, an additional 13 assessable patients had to be
entered. If 10 or more objective responses were observed among
the 30 assessable patients, the treatment would be considered
worthy of further consideration.
The Mann–Whitney U-test and Fisher’s exact test were used to
evaluate the differences, respectively, in continuous and catego-
rical variables between responders and non-responders.
The one-sample Wilcoxon signed-rank test and McNemar’s Test
were used to examine the change of expression, respectively, in
continuous and categorical molecular parameters, among all
tumours, between the pretreatment biopsy and surgery.
The change of expression was also evaluated in responders and
non-responders, and differences between groups were also tested
using the Mann–Whitney U-statistics.
To assess whether oestradiol levels decreases or increases during
treatment, a linear mixed models for repeated-measures data were
used. In the regression analysis, oestradiol levels were logarith-
mically transformed to reduce skewedness.
Disease-free survival (DFS) was calculated from the date of
surgery to any relapse, the appearance of a second primary cancer,
or death, whichever occurred first.
Estimation of the DFS was performed using the Kaplan–Meier
method, and the log-rank test was used to assess the survival
difference between responders and non-responders.
All analyses were performed with the SAS software (SAS
Institute, Cary, NC, USA). All tests were two sided.
RESULTS
Thirty-nine consecutive patients were considered for the study
and 37 were eligible. Two patients were excluded, one because of
synchronous bone metastasis and one because of multifocal
tumour with different receptor status.
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evaluable for response (two refused further treatment, one received
anastrozole instead of letrozole and two did not achieve
postmenopausal status within 3 months and were submitted to
surgery).
Thirty-two patients were therefore considered evaluable for
response. Median age was 41.5 years (range, 33–54 years). Twenty-
eight patients received 3-month triptorelin and four patients
received 28-day goserelin. Median duration of total treatment from
initiation of GnRH analogue was 5.2 months (IQ range, 4.6–5.6),
while median duration of letrozole was 4 months (IQ range,
3.4–4.4).
Table 1 reports the clinical and biological characteristics of the
tumours at the pretreatment biopsy and at surgery. All but one
tumour maintained ER positivity at surgery, while downregulation
of PgR was observed in 26 patients. Treatment also induced
downregulation of proliferative activity with 9 (28%) patients
showing a Ki-67 420% at surgery as compared with 17 (53%)
patients with high proliferative activity in initial biopsy
(McNemar’s test Po0.05). No change was observed in HER2
overexpression.
The changes between pretreatment and the post-treatment
values for PgR and Ki-67 in each patient are reported in Figure 1.
One patient (3%) obtained a complete clinical response, which
was confirmed as a pCR at pathological examination. Fifteen
patients (47%) obtained a clinical and imaging partial response
giving an overall response rate of 50% (95% CI 32–68%). Sixteen
patients were stable and no patient progressed during treatment.
Breast-conserving surgery was performed in 15 patients (47%)
while 17 patients (53%) were submitted to mastectomy. Twenty-
two patients received anthracycline-containing chemotherapy as
adjuvant treatment, while 10 patients continued endocrine
therapy.
Median follow-up was 36 months (range, 6–51). We observed
seven recurrences (one locoregional and six distant recurrences)
and two deaths. Three-year DFS was 76% (95% CI 59–93%) (83%
in clinical responders, 70% in non-responders, log-rank test
P-value 0.23.).
Univariate analysis showed that clinical response was positively
associated with duration of letrozole treatment which lasted 4.2
months (IQ range, 3.7–4.7) for clinical responders vs 3.4 months
(IQ range, 2.0–5.4) for patients obtaining stable disease (Mann–
Whitney U-test Po0.05). Clinical response was positively asso-
ciated also with age, since median age in responding patients was
39 vs 44.5 years for non-responding patients (Mann–Whitney
U-test Po0.05). Twelve (67%) patients with PgR levels X70%,
corresponding to the median value of PgR, and four patients (29%)
with PgR o70% had a clinical response (Fisher’s exact test
P¼0.07).
Twenty-three patients had repeated measurements of oestradiol
at different time points during treatment. After GnRH analogue
median oestradiol was 16pgml
 1 (IQ range, 10–23). Linear mixed
regression for repeated-measures data showed that there was no
significant change in oestradiol levels upon treatment with
letrozole (Figure 2). The oestradiol time course was not correlated
with clinical response (Figure 2). Gonadotrophins were measured
at the same time points of oestradiol and confirmed the
suppression of LH and FSH.
Treatment was well tolerated and no patient discontinued
therapy because of side effects. Main toxicities are reported in
Table 2.
Molecular analysis was performed in 27 patients for whom
tumour tissue from either pretreatment biopsy or definitive
surgery was available. High levels of ERa-p-Ser
118 were detected
Table 1 Clinical and biological characteristics of tumours at baseline and
at surgery
Trucut biopsy Surgery
Evaluable patients 32 32
a
Clinical stage
T2/T3 24/5 —
T4b 3
N0/N1 7/25
Pathological stage
T0 — 1
T1c/T2 10/16
T3/T4 4/1
N0/N1 3/6
N2/N3 12/5
ER status
Negative 0 1
10–49% 3 4
X50% 29 26
PgR status
b
Negative 0 25
10–49% 11 3
X50% 21 2
Ki-67
X20% 17 9
o20% 15 22
HER2 overexpression
3+ 5 5
2+ 4 6
1+/absent 23 20
EGFR expression
c 05
aOne patient was not evaluable for biological characteristics at surgery because she
achieved a pCR.
bOne patient with PgR o10% was included among PgR negative.
cTumours expressing any percentage of stained cells were considered positive.
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Figure 1 Change between pretreatment and post-treatment levels of PgR, Ki-67 and for ERa-p-Ser
118 in each patient.
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(Wilcoxon signed-rank test Po0.0001; Table 2). The change
between pretreatment and the post-treatment values in each
patient for ERa-p-Ser
118 are reported in Figure 1.
Oestrogen receptor-b1 (ER-b1) immunoreactivity was detectable
in 24 patients and was significantly upregulated after treatment
(Wilcoxon signed-rank test Po0.05; Table 3).
Neither EGFR nor its phosphorylated form (p-EGFR) was
detectable in any sample in the pretreatment biopsy, while after
treatment very few cells (median value 5% range, 3–10%)
positively stained for EGFR in five surgical specimens. Phosphory-
lated HER2 was expressed in 10 patients (37%) at baseline. Four
out of five patients with HER2 IHC 3 þ stained positively for
p-HER2 Phosphorylated-p38 (MAPK) was detected in 11 patients
and p-p44/42 (MAPK) was detected in all patients except 2 at
baseline and their levels remained substantially unchanged after
treatment (Table 3).
Univariate analysis failed to show any association between
baseline values of any molecular parameter and clinical response.
No significant difference between baseline and post-treatment
values were observed for any parameter among responding and
not responding patients (Table 3).
DISCUSSION
Preoperative treatment of patients with endocrine-responsive
breast cancer represents a challenge for patients with the disease,
medical oncologists, surgeons and pathologists. Despite the
addition of taxanes to anthracyclines, the pCR rate after
preoperative chemotherapy in hormone receptor-positive tumours
remains relatively low (Kaufmann et al, 2006).
Primary endocrine therapy is able to induce a high rate of
objective remissions and breast-conserving surgery (Abrial et al,
2006). Preoperative endocrine therapy has been historically
60
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Figure 2 Time course of oestradiol levels upon treatment with letrozole
according to clinical response. Time 0 is represented by the oestradiol
levels obtained after GnRH analogue. Dashed line represents oestradiol
time course in clinical responders and continuous line in non-responders.
Table 2 Main toxicities
Toxicity (N¼30) G1 N (%) G2 N (%)
Hot flashes 3 (10%) 17 (56.7%)
Arthromyalgia 5 (16.7%) 2 (6.7%)
Headache 4 (13%) 0
Night sweating 2 (6.7%) 2 (6.7%)
Rash 1 (3.3%) 1 (3.3%)
Nausea 1 (3.3%) 1 (3.3%)
Neurological 2 (6.7%) 0
Astenia 1 (3.3%) 0
Dizziness 1 (3.3%) 0
Table 3 Basal levels and changes of molecular parameters after treatment according to clinical response on 27 evaluable patients
No. of positive
samples at trucut
Median value at
trucut
a [IQR]
No. of positive
samples at surgery
Median difference between
trucut and surgery [IQR] P-value
ERa-p-Ser
118
Total 27/27 90 [90, 90] 26/26  25 [ 65,  5] o0.001
b
CR 13/13 90 [90, 90] 12/12  25 [ 55,  5] 0.68
c
NR 14/14 90 [90, 90] 14/14  25 [ 75,  5]
pHER2
Total 10/27 0 [0, 5] 8/26 0 [ 5, 0] 0.49
b
CR 6/13 0 [0, 5] 5/12 0 [0, 0] 0.73
c
NR 4/14 0 [0, 3] 3/14 0 [ 5, 0]
ER-b
Total 23/27 48 [5, 90] 23/26 10 [0, 60] 0.02
b
CR 11/13 60 [5, 90] 10/12 10 [0, 60] 0.66
c
NR 12/14 41 [5, 80] 13/14 9 [ 10, 42]
p-p38
Total 11/27 0 [0, 3] 13/26 0 [ 3, 20] 0.10
b
CR 5/13 0 [0, 3] 5/12 0 [ 3, 20] 0.68
c
NR 6/14 0 [0, 3] 8/14 0 [ 3, 12]
p-p44/42
Total 23/27 10 [5, 15] 18/26  5[  10, 28] 0.78
b
CR 12/13 10 [10–15] 8/12  3[  10, 30] 0.66
c
NR 11/14 9 [3–10] 10/14  5[  10, 24]
CR¼clinical responders; IQR¼interquartile range; NR¼non-responders.
aValues are expressed as percentage of stained cells.
bChange of the expression of molecular
parameters among all tumours assessed by the Wilcoxon signed-rank test.
cChange of the expression of the molecular parameters between clinical responders and non-
responders assessed by the Mann–Whitney U-test.
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srestricted to postmenopausal women. Data arising from very small
studies have been reported in premenopausal women treated with
preoperative GnRH analogue (Gazet et al, 2001; Miller et al, 2001).
Aromatase inhibitors in combination with GnRH analogue have
not been systematically studied as primary therapy in premeno-
pausal women with hormone receptor positive locally advanced
operable breast cancer. Experience in advanced disease is also
limited, ranging from anecdotal reports to small phase II studies
(Forward et al, 2004; Dowsett et al, 2005). The present study
showed that endocrine therapy inducing a maximal oestrogen
blockade is feasible in premenopausal women and effective in
terms of response rate (50%, 95% CI 32–68%). Results are in line
with those already reported in postmenopausal women with
aromatase inhibitors where the response rate ranged from 24 to
35%, when considering ultrasound evaluation (Eiermann et al,
2001; Smith et al, 2005). In our study, one patient (3%) achieved a
pCR and 47% of patients were submitted to breast-conserving
surgery. These figures too are comparable with those reported in
randomised trials with preoperative aromatase inhibitors in
postmenopausal patients. Preoperative endocrine therapy has
been associated with a very low rate of pCR ranging from 1 to
8% (Kaufmann et al, 2006). The value of pCR as surrogate end
point of clinical outcome in ER-positive tumours after primary
chemotherapy, which was called into question in former studies,
was recently confirmed by the results of a large retrospective study
showing that pCR was positively associated with outcome in both
ER-negative and ER-positive tumours (Ring et al, 2004; Guarneri
et al, 2006), but no data after primary endocrine therapy are
available. A significantly increased response rate was reported with
6 months as compared with 3 months of preoperative letrozole
therapy (Paepke et al, 2006). It may therefore be that a higher pCR
rate might be observed with prolonged treatment in the
preoperative setting.
As expected, treatment induced a significant downregulation of
both PgR expression and proliferative activity, although these were
not significantly correlated with clinical response (Miller et al,
2006), although a trend for a greater reduction of Ki-67 was
observed in responders.
Our results confirm a possible role for the expression of PgR in
determining the endocrine responsiveness of the tumour. High
levels of PgR were positively associated with the occurrence of a
clinical response if compared with lower levels although the
difference was of borderline significance.
An important issue relates to the extent of oestrogen suppres-
sion occurring upon treatment with an aromatase inhibitor in
combination with a GnRH analogue in premenopausal women.
Available data range from anecdotal reports to small phase II
studies and include mainly the second-generation steroidal
inhibitor formestane other than the non-steroidal inhibitors
anastrozole and vorozole. In all reports, a further inhibition of
oestradiol levels was observed after therapy with aromatase
inhibitor (Dowsett et al, 1992, 1999; Celio et al, 1999; Forward
et al, 2004). In our study, we evaluated the levels of oestradiol
at different time points during the study to determine the
hormonal status. We acknowledge that our data are limited
because of the heterogeneity of time points of the determinations
and the multiple laboratories employed, other than the lack of
adequately sensitive test for measuring oestradiol. We found
that oestradiol levels were maintained in the postmenopausal
range. We observed a slight and not significant further suppression
of oestradiol after letrozole administration only in 13 patients
out of 23. Whether the extent of oestradiol suppression may
affect the clinical response is currently unknown. Although our
data in a limited number of patients failed to show any correlation
between oestradiol time course and clinical response, the issue
of oestrogen suppression in premenopausal women receiving
aromatase inhibitors needs to be further addressed, given these
drugs are currently investigated in the adjuvant setting in large
phase III trials. On the other hand, two patients failed to reach a
full-ovarian function suppression within 3 months after the first
administration of 3-month triptorelin as documented by persisting
menstrual cycle and oestradiol levels within the range of
premenopause and were submitted to surgery. The failure of
the 3-month GnRH analogue formulation in achieving
ovarian function suppression has been previously reported either
in breast and in prostate cancer patients (Yri et al, 2006; Schmid
et al, 2007).
Few data are available on the molecular changes occurring in
vivo after neoadjuvant therapy with aromatase inhibitors and their
predictive value on clinical response. Our study population was
highly selected according to the expression of both steroid
hormone receptors. Molecular analysis showing high baseline
levels of ERa-p-Ser
118 and the absent or negligible expression of
EGFR and HER2 in all patients emphasise the endocrine-sensitive
nature of our population.
Almost all available data on mechanisms of resistance to
aromatase inhibitors are derived from preclinical models using
long-term oestrogen-deprived (LTED) cells which supposedly
mimic the oestrogen depletion seen clinically with letrozole
(Brodie et al, 2005; Dowsett et al, 2005). In these models, an
upregulation of the ERa-p-Ser
118 following an activation of growth
factor pathway signalling (EGFR, IGFR) and the activation of MAP
kinase has been demonstrated when tumours started to grow
despite letrozole (Chen et al, 2006).
Ser
118 represents the major site of phosphorylation of ER upon
binding with oestradiol (Lannigan, 2003). Baseline levels of ERa-p-
Ser
118 have been positively associated with favourable tumour
characteristics, with a better outcome after therapy with tamoxifen
and with expression of PgR (Murphy et al, 2004a,b). It has been
hypothesised that, as distinct from what occurs in vitro, ERa-p-
Ser
118 is a marker of a functional ligand-dependent pathway in
primary breast tumours and is involved in the mechanisms by
which the oestradiol/ERa complex regulates downstream signalling
(Murphy et al, 2004b).
We may speculate that the downregulation of the ERa-p-Ser
118
we observed after treatment is a consequence of the suppressed
levels of circulating oestrogens, suggesting the occurrence of a
reduced oestrogen-induced transcription, leading finally to a
clinical response. In a previous study with gefitinib plus or minus
anastrozole, the decrease of ERa-p-Ser
118 was associated with
clinical response (Polychronis et al, 2005). Therefore, we might
have expected that non-responders should not experience a
decrease of ERa-p-Ser
118, but rather an increased phosphorylation
as a consequence of a ligand-independent activation which is a
putative mechanism of endocrine resistance (Brodie et al, 2005;
Chen et al, 2006). However, in our study no difference in the
extent of the decreased phosphorylation was observed in
responders or non-responders, and we saw no increase in EGFR
or HER2 expression or in phosphorylated MAP kinase activity
in the clinical non-responders. It is possible that our non-
responders were not inherently resistant, but merely not treated
for long enough.
Our results on the correlation between biomarkers and clinical
response, however, should be considered with caution given the
small number of patients included in this analysis.
The significance and the role of ER-b and the interaction with
ER-a are unclear. The ratio ERa:ER-b within tumour cells has
been hypothesised to play a functional role in cell growth (Shaw
et al, 2006). Conflicting data have been reported on the role of
ER-b either in vitro and in vivo, in that results from preclinical and
clinical studies have associated ER-b either positively (protein
expression) or negatively (mRNA) with prognosis and response to
endocrine treatment (Cappelletti et al, 2004; Saji et al, 2005). The
results of our study, showing a significant upregulation of ER-b
after treatment irrespective of clinical response, do not help to get
further insight into this issue.
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therapy with aromatase inhibitors, in combination with a GnRH
analogue, is safe and effective in premenopausal women with
locally advanced operable breast cancer. A biological response, in
terms of downregulation of the oestrogenic signalling, was
observed in all patients, and clinical response in 50% of the
patients. The trend to improved response rate observed with
longer duration in the present study and in previously published
studies support the development of tailored endocrine therapy of
longer duration in selected populations of premenopausal patients
with endocrine-responsive tumours.
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